The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
muscle function there's pretty good evidence that at least rapamycin can prevent sarcopenia i don't think there's a lot of data yet on improvements in muscle function but you could do things like you know grip strength walk speed things like that
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
again that's why i you know often will gravitate back towards what are the functional consequences we can actually measure right sure i get it you think that treating a mouse with rapamycin is going to cause sarcopenia let's do the experiment and find out the answer is no it doesn't right
you know the expectation was because mtor plays such a big role in muscle synthesis that if you inhibit mtor with rapamycin or caloric restriction which is a potent inhibitor of mtor that you would actually uh see accelerated sarcopenia and that just isn't the observation in laboratory animals again we have to be careful not to extrapolate to people but but it doesn't seem to be the case that you lose muscle muscle mass and function in the way that people would define sarcopenia
I think that um uh most much like rapamycin most functional measures of Aging seem to be preserved in calorically restricted animals including measures of Frailty and measures of sarcopenia
and you know this the same thing again is true with rapamycin this actually surprised a lot of people when the first studies were done because you know the expectation was because mtor plays such a big role in muscle synthesis that if you inhibit mtor with rapamycin or caloric restriction which is a potent inhibitor of mtor that you would actually see accelerated sarcopenia and that just isn't the observation in laboratory animals
the reality turns out to be the opposite that it seemed to be the case certainly in rats probably in mice we don't have data yet in people frustratingly but certainly in rodents that you can treat them with Romy throughout adulthood and actually preserve muscle mass into old age
most functional measures of Aging seem to be preserved in calorically restricted animals including measures of Frailty and measures of sarcopenia
the expectation was because mtor plays such a big role in muscle synthesis that if you inhibit mtor with rapamycin or caloric restriction which is a potent inhibitor of mtor that you would actually uh see accelerated sarcopenia and that just isn't the observation in laboratory animals
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.